Pivotal Study of NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 3, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 31, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 24, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

Fiscal Year 2023 Fourth Quarter Highlights Net sales of $91.1 million increased 4.7% compared to the prior-year quarter Med Tech net sales of $26.5 million increased 17.2% Med Device net sales of $64.6 million increased 0.3% Gross margin of 50.9% declined 250 basis points year over year GAAP loss

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 20, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

Announces preliminary Fiscal Year 2023 net sales in the range of $338 million to $339 million LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 8, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 11, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

Fiscal Year 2023 Third Quarter Highlights Net sales of $80.7 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $22.9 million increased 16.6% Med Device net sales of $57.8 million increased 6.4% Gross margin of 50.2% decreased 200 basis points year over year GAAP loss

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 13, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 28, 2023-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

Fiscal Year 2023 Second Quarter Highlights Net sales of $85.4 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $24.5 million increased 29.7% Med Device net sales of $60.9 million increased 2.6% Gross margin of 52.8% increased 100 basis points year over year GAAP loss

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 20, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 15, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Nov. 17, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today

AngioDynamics , The PERT Consortium™ and Viz.ai partner on APEX Study to facilitate future enrollment to bring innovative treatment to patients with PE LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 31, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused

Fiscal Year 2023 First Quarter Highlights Net sales of $81.5 million increased 5.9% compared to the prior-year quarter Med Tech net sales of $22.8 million increased 29.6% Med Device net sales of $58.7 million decreased 1.1% Gross margin of 51.9% declined 20 basis points year over year GAAP loss per

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 8, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 3, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

Fiscal Year 2022 Fourth Quarter Highlights Net sales of $87.0 million increased 13.2% compared to the prior-year quarter Gross margin of 53.4% declined 170 basis points year over year GAAP loss per share of $0.16 and adjusted earnings per share of $0.01 Cash and cash equivalents at May 31, 2022

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 15, 2022-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today